Drugs / RO7443904
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05219513 | Feb 2022 → Jul 2024 | non-Hodgkin lymphoma | Hoffmann-La Roche | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7443904 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05219513 ↗ |
| Route | Intravenous | “RO7443904 will be administered by subcutaneous (SC) or IV infusion” NCT05219513 ↗ |
| Route | Subcutaneous | “RO7443904 will be administered by subcutaneous (SC) or IV infusion” NCT05219513 ↗ |